arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

BIO-TECHNE Corp

TECH
$72.30 ▲ +0.38 (+0.52%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Neutral
auto_awesome

Analytical Summary

BIO-TECHNE Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $11.4B
Dividend Yield 0.44%
Revenue Growth 5.2%
Op. Margin 8.4%
ROIC None
FCF / Share $1.63
Trailing P/E 153.8x
Price / Book
FCF Yield 2.3%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.22B
↑ +5.2%
Net Income Profit after all expenses
$73.40M
↓ -56.3%
Operating Margin Operating profit as % of sales
8.4%
↓ -53.0% 52th
FCF / Share Free cash flow per share
$1.63
↑ +8.8%

Health Breakdown

Profitability
63
Financial Health
74
Cash Quality
93

Dividend History

Dividend / share · sourced from SEC filings
$0.32 Latest / share
+0.0% YoY
+0.4% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 69 quarters